nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2011 | Original Article

¹²³I-MIBG imaging detects cardiac involvement and predicts cardiac events in Churg-Strauss syndrome

verfasst von: Yoriko Horiguchi, Yukiko Morita, Naomi Tsurikisawa, Kazuo Akiyama

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In Churg-Strauss syndrome (CSS) it is important to detect cardiac involvement, which predicts poor prognosis. This study evaluated whether ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy could detect cardiac damage and predict cardiac events in CSS.

Methods

¹²³I-MIBG scintigraphy was performed in 28 patients with CSS, 12 of whom had cardiac involvement. The early and delayed heart to mediastinum ratio (early H/M and delayed H/M) and washout rate were calculated by using ¹²³I-MIBG scintigraphy and compared with those in control subjects.

Results

Early H/M and delayed H/M were significantly lower and the washout rate was significantly higher in patients with cardiac involvement than in those without and in controls (early H/M, p = 0.0024, p = 0.0001; delayed H/M, p = 0.0002, p = 0.0001; washout rate, p = 0.0012, p = 0.0052 vs those without and vs controls, respectively). Accuracy for detecting cardiac involvement was 86% for delayed H/M and washout rate and 79% for early H/M and B-type natriuretic peptide (BNP). Kaplan-Meier analysis showed significantly lower cardiac event-free rates in patients with early H/M ≤ 2.18 and BNP > 21.8 pg/ml than those with early H/M > 2.18 and BNP ≤ 21.8 pg/ml (log-rank test p = 0.006).

Conclusion

Cardiac sympathetic nerve function was damaged in CSS patients with cardiac involvement. ¹²³I-MIBG scintigraphy was useful in detecting cardiac involvement and in predicting cardiac events.

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92.CrossRefPubMed

Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999;8:179–89.CrossRefPubMed

Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414–9.CrossRefPubMed

Sinico RA, Toma LD, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926–35.CrossRefPubMed

Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26–37.CrossRef

Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277–301.PubMed

Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587–94.CrossRefPubMed

Bougarit A, Toumelin PL, Pagnoux C, Cohen P, Mahr A, Guern VL, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005;84:323–30.CrossRef

Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17–28.CrossRef

10.

Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques Jr S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620–4.PubMed

11.

Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:939–50.CrossRefPubMed

12.

Watanabe K, Takahashi T, Miyajima S, Hirokawa Y, Tanabe N, Kato K, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med 2002;43:1476–81.PubMed

13.

Merlet P, Valette H, Dubois-Randé J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–7.PubMed

14.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661–7.CrossRefPubMed

15.

Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004;92:80–7.CrossRefPubMed

16.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094–100.CrossRefPubMed

17.

Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671–8.PubMed

18.

Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138–47.PubMed

19.

Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–42.CrossRefPubMed

20.

Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88:236–43.CrossRef

21.

Frustaci A, Gentiloni N, Chimenti C, Natale L, Gasbarrini G, Maseri A. Necrotizing myocardial vasculitis in Churg-Strauss syndrome: clinicohistologic evaluation of steroids and immunosuppressive therapy. Chest 1998;114:1484–9.CrossRefPubMed

22.

Terasaki F, Hayashi T, Hirota Y, Okabe M, Suwa M, Deguchi H, et al. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome. Heart Vessels 1997;12:43–8.CrossRefPubMed

23.

Simantirakis EN, Prassopoulos VK, Chrysostomakis SI, Kochiadakis GE, Koukouraki SI, Lekakis JP, et al. Effect of asynchronous ventricular activation on myocardial adrenergic innervation in patients with permanent dual-chamber pacemakers; an ¹²³I-metaiodobenzylguanidine cardiac scintigraphic study. Eur Heart J 2001;22:323–32.CrossRefPubMed

24.

Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008–19.PubMed

25.

Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155–63.PubMed

26.

Wassmuth R, Göbel U, Natusch A, Schneider W, Kettritz R, Dietz R, et al. Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. J Card Fail 2008;14:856–60.CrossRefPubMed

27.

Pelà G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G. Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol 2006;97:1519–24.CrossRefPubMed

28.

Morita H, Yokoyama I, Yamada N, Uno K, Nagai R. Usefulness of ¹⁸FDG/¹³N-ammonia PET imaging for evaluation of the cardiac damage in Churg-Strauss syndrome. Eur J Nucl Med Mol Imaging 2004;31:1218.CrossRefPubMed

29.

Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005;11:498–503.CrossRefPubMed

30.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212–21.CrossRefPubMed

31.

Germano G, Erel J, Kiat H, Kavanagh PB, Berman DS. Quantitative LVEF and quantitative regional function from gated thallium-201 perfusion SPECT. J Nucl Med 1997;38:749–54.PubMed

32.

Cwajg E, Cwajg J, He ZX, Hwang WS, Keng F, Nagueh SF, et al. Gated myocardial perfusion tomography for the assessment of left ventricular function and volumes: comparison with echocardiography. J Nucl Med 1999;40:1857–65.PubMed

Titel: 123I-MIBG imaging detects cardiac involvement and predicts cardiac events in Churg-Strauss syndrome
verfasst von: Yoriko Horiguchi
Yukiko Morita
Naomi Tsurikisawa
Kazuo Akiyama
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1617-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

The Clinical Audit Courses of the Committee for Accreditation of Nuclear Medicine Departments (CANMD)

Comparison of 18F- and 11C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography

In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease

Reversible brain hypometabolism associated with central nervous system systemic lupus erythematosus

Molecular imaging in cancer treatment

Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions?